To clarify my earlier statement: For those who have been administered the first dose of a particular vaccine and in case of the unavailability of the second dose of the same - as an alternative, another vaccine can be administered. That said, the efficacy and the immunogenicity of the combination are dependent on the ongoing studies conducted by regulators.
The first nasal vaccine againstCovid-19, developed by Bharat Biotech, has received regulator's nod for conducting phase 2 and 3 clinical trials, the Department of Biotechnology said on Friday.
Phase 1 clinical trial has been completed in age groups ranging from 18 to 60 years, it said.
"Bharat Biotech's intranasal vaccine is the first nasal vaccine that has received the regulatory approval for phase 2/3 trials," the DBT said. (PTI)
Kerala reports 20,452 fresh COVID cases, 16,856 recoveries, and 114 deaths in the last 24 hours Active cases: 1,80,000 Total recoveries: 34,53,174 Death toll: 18,394 (ANI)